Peripheral T-Cell Lymphoma Overview
Peripheral T-cell lymphomas (PTCLs) are an uncommon and heterogeneous group of clinically aggressive types of non-Hodgkin lymphoma (NHL) that develop in mature white blood cells called “T cells” and “natural killer (NK) cells.” It is Peripheral T- Cell Lymphoma’s origin in the lymphatic system that gave it the name peripheral T-cell lymphoma. In the case of PTCL, the term “peripheral” does not refer to the extremities, but identifies PTCL as cancer that arises in the lymphoid tissues outside of the bone marrow such as lymph nodes, spleen, gastrointestinal tract, and skin. Signs and symptoms of Peripheral T- Cell Lymphoma include asymptomatic lymphadenopathy, Fever, night sweats, poor appetite, and weight loss including fatigue, and painless swelling in the neck, armpit, or groin (due to an enlarged lymph node). Different staging systems have been proposed for Peripheral T- Cell Lymphomas.
Peripheral T-Cell Lymphoma Epidemiology Insights
The total Peripheral T-cell Lymphoma market size in the 7MM is USD 564 million in 2021 and is projected to grow during the forecast period (2022-2032).
The total incident population of Peripheral T- Cell Lymphomas in the 7MM comprised of 18,027 cases in 2021 and is projected to increase during the forecast period.
The total Peripheral T- Cell Lymphomas market size in the United States is expected to increase with a CAGR of 4.9% during the study period (2019–2032).
Click here to learn more about the Peripheral T-Cell Lymphoma Market Landscape
The Report Covers the Peripheral T-Cell Lymphoma Epidemiology Segmented by:
Total Peripheral T-Cell Lymphoma incident cases
Total Peripheral T-Cell Lymphoma prevalent cases
Total Peripheral T-Cell Lymphoma diagnosed cases
Total Peripheral T-Cell Lymphoma treatment cases
Peripheral T-Cell Lymphoma Market Outlook
The therapeutic challenge for Peripheral T- Cell Lymphoma remains as these are aggressive and rare cancers which are extremely diverse. To make matters worse, it remains a disease with a poor prognosis and limited treatment options, especially in comparison to its B-cell counterparts. The existing treatment options for Peripheral T- Cell Lymphoma include CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone), which emerged as the standard of care in the treatment of aggressive non-Hodgkin lymphomas in the 1990s when the distinction between peripheral T-cell lymphoma and aggressive B-cell-derived non-Hodgkin lymphoma became apparent. The treatment options for Peripheral T- Cell Lymphoma include combination chemotherapy regimens typically CHOP-based chemotherapy or EPOCH (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone), localized radiotherapy, stem cell transplants, and steroid therapy.
Key Companies Working in the Peripheral T-Cell Lymphoma Market
Pfizer
Huya Biosciences International
Solasia Pharmaceuticals
Acrotech Biopharmaceuticals
Takeda
Viracta Pharmaceuticals
And many others
Peripheral T-Cell Lymphoma Therapies Covered and Analyzed in the Report:-
XALKORI (crizotinib)
HIYASTA (tucidinostat)
DARVIAS (darinaparsin)
BELEODAQ (belinostat)
ADCETRIS (brentuximab vedotin)
Nanatinostat
Learn more about the Key Companies and Emerging Therapies in the Peripheral T-Cell Lymphoma Market
Table of Contents
Key Insights
Peripheral T-Cell Lymphoma Introduction
Executive Summary of Peripheral T-Cell Lymphoma
Disease Background and Overview
Epidemiology and patient population
Peripheral T-Cell Lymphoma Emerging Therapies
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @ Peripheral T-Cell Lymphoma Market Outlook
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services